Pharmacological and neurochemical investigations of lead-induced hyperactivity.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001590:Benztropine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002746:Chlorpromazine / Q000494:pharmacology; D003642:Deanol / Q000494:pharmacology; D005260:Female; D005277:Fenfluramine / Q000494:pharmacology; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced*; D007854:Lead / Q000494:pharmacology*; D007980:Levodopa / Q000494:pharmacology; D008774:Methylphenidate / Q000494:pharmacology; D008781:Methyltyrosines / Q000494:pharmacology; D051379:Mice; D010830:Physostigmine / Q000494:pharmacology; D011247:Pregnancy; D013268:Stimulation, Chemical; D013574:Synaptosomes / Q000187:drug effects
D008781:Methyltyrosines; D001590:Benztropine; D008774:Methylphenidate; D005277:Fenfluramine; D003642:Deanol; D007854:Lead; D007980:Levodopa; D001285:Atropine; D010830:Physostigmine; D001058:Apomorphine; D002746:Chlorpromazine